9 results
Pain Assessment and Management Initiative (PAMI) - Non-Opioid Analgesics - Agents and Dosing

#Management #Pain #Pharmacology #NonOpioid
Pain Assessment ... and Management Initiative ... #Pain #Pharmacology ... #NonOpioid #Analgesics ... #Medications #Doses
Alternatives to opioids for pain management in the emergency department decreases opioid usage and maintains patient
to opioids for pain ... management in the ... #Pharmacology # ... NonOpioid #Alternatives ... PainSyndromes #Indications
Comparison of anti-diabetic or anti-hyperglycemic agents

There are numerous anti-hyperglycemic agents available to manage Type 2 diabetes.
Each class of medications ... risks, and therapy should ... #pharmacology #pharmacotherapy ... table #comparison #management ... #medications #diabetes
Diabetic Peripheral Neuropathy - Pharmacotherapy

Peripheral neuropathy is a common microvascular complication of diabetes. In clinic patients
Diabetic Peripheral ... complication of diabetes ... clinic patients should ... #Pharmacology # ... Management #Medications
In 2018, opioid withdrawal should be considered a buprenorphine deficiency. Otherwise, a multitude of comparatively ineffective
opioid withdrawal should ... @emupdates #Management ... #Pharmacology # ... Pain #NonOpioid
Lyrica (Pregabalin) 
Indications: Neuropathy (diabetic, postherpetic neuralgia, fibromyalgia, & spinal cord injury), Adjunctive therapy for partial-onset
: Neuropathy (diabetic ... and for nerve pain ... (including diabetic ... Patients mood should ... Lyrica #Pregabalin #Pharmacology
Taken from Dr Motov's work on a CERTA regime.
This is published in conjunction with the CERTA
analgesia by using medication ... and protocols should ... @Gas_Craic #Management ... #Pharmacology # ... NonOpioid #Opiate
Lidocaine 5% Patch (Lidoderm) 
Medicare Covered Indications 
1. Post-herpetic neuralgia pain 
2. Diabetic peripheral neuropathy 
3.
Diabetic peripheral ... , shoulder injuries ... Remember that is should ... Disposal should ... Patch #Lidoderm #Pharmacology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
semaglutide, the same medication ... Patients should ... been shown non-inferior ... #semaglutide #Diabetes ... #Pharmacology #